Akers Biosciences starts asthma assay trials
This article was originally published in Clinica
Akers Biosciences has begun clinical trials of its rapid point-of-care test for asthma in around 200 patients. The disposable Breath Asthma Check assay measures the acidity of exhaled breath condensate; this indicates airway acidity, which is associated with airway inflammation. The test could provide an inexpensive, rapid screening aid in the diagnosis of early-stage asthma, and may also be used as a compliance tool for physicians to ensure successful drug therapy regimens. Thorofare, New Jersey-based Akers will use the trial results to submit regulatory approval applications for the test in the US and EU. This is scheduled for the third quarter of 2011.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.